CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies  by Klyuchnikov, Evgeny et al.
Biol Blood Marrow Transplant 20 (2014) 382e386American Society for Blood
ASBMT
and Marrow TransplantationCD34þ-Selected Stem Cell Boost without
Further Conditioning for Poor Graft Function
after Allogeneic Stem Cell Transplantation in
Patients with Hematological Malignancies
Evgeny Klyuchnikov 1, Jean El-Cheikh 2, Andreas Sputtek 3,
Michael Lioznov 1, Boris Calmels 2, Sabine Furst 2,
Christian Chabannon 2, Roberto Crocchiolo 2,
Claude Lemarié 2, Catherine Faucher 2, Ulrike Bacher 1,
Haefaa Alchalby 1, Thomas Stübig 1, Christine Wolschke 1,
Francis Ayuk 1, Marie-Luise Reckhaus 3, Didier Blaise 2,
Nicolaus Kröger 1,*
1Department for Stem Cell Transplantation, University Cancer Center Hamburg-Eppendorf, Hamburg,
Germany
2Department for Stem Cell Transplantation, Institut Paoli Calmettes, Marseille, France
3 Institute for Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg,
GermanyArticle history:
Received 7 May 2013
Accepted 30 November 2013
Key Words:
Allogeneic hematopoietic stem
cell transplantation (HSCT)
Poor graft function
CD34þ-selected cells
Stem cell boostFinancial disclosure: See Acknowl
* Correspondence and reprint r
ment for Stem Cell Transplantation
Hamburg, Martinistrasse, 52, 2024
E-mail address: n.kroeger@uke
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
We retrospectively analyzed outcomes of a CD34þ-selected stem cell boost (SCB) without prior conditioning
in 32 patients (male/22; median age of 54 years; range, 20 to 69) with poor graft function, deﬁned as neu-
trophils 1.5 x 109/L, and/or platelets 30 x 109/L, and/or hemoglobin 8.5 g/dL). The median interval be-
tween stem cell transplantation and SCB was 5 months (range, 2 to 228). The median number of CD34þ and
CD3þ cells were 3.4 x 106/kg (.96 to 8.30) and 9 x 103/kg body weight (range, 2 to 70), respectively. Hema-
tological improvement was observed in 81% of patients and noted after a median of 30 days (range, 14 to 120)
after SCB. The recipients of related grafts responded faster than recipients of unrelated grafts (20 versus 30
days, P ¼ .04). The cumulative incidence of acute (grade II to IV) and chronic graft-versus-host disease (GVHD)
after SCB was 17% and 26%, respectively. Patients with acute GVHD received a higher median CD3þ cell dose.
The 2-year probability of overall survival was 45%. We suggest that SCB represents an effective approach to
improve poor graft function post transplantation, but optimal timing of SCB administration, anti-infective,
and GVHD prophylaxis needs further evaluation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION patients with persisting thrombocytopenia, the use of
Poor graft function (PGF) is a relatively rare post-
transplantation complication associated with infections,
bleeding, and secondary iron overload due to increased
transfusions. There are various therapeutic approaches that
potentially could improve PGF, such as stimulation of the
already transplanted stem cells (eg, use of growth factors
[1,2]), or administration of new stem cells from same donor
(eg, a second allogeneic hematopoietic stem cell trans-
plantation [HSCT] [3-5], or use of unmanipulated [6,7] or
CD34þ-selected stem cell boost [SCB] [8-11]).
The stimulation of the already transplanted stem cells by
the use of myeloid growth factors was found to increase the
production of neutrophils, but, on the other hand, to delay
the platelet recovery, and moreover was associated with
increased acute (a) and chronic (c) graft-versus-host disease
(GVHD) rates [2]. In addition, the safety of the long-term use
of growth factors remains unclear [12,13]. Further, foredgments on page 386.
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13.11.034thrombopoietin receptor agonists has not been tested in the
setting of allogeneic HSCT. Thus, the use of growth factors
represents a temporary approach that is unable to solve the
cause of PGF. The stimulation of transplanted stem cells could
also be achieved by modulation of the microenvironment of
the stem cell niche. In this setting, the use of mesenchymal
stem cells could also be a possible option to improve PGF, as
their positive effect on engraftment had been shown [14-16].
Transplantation of additional stem cells could be per-
formed as a regrafting after administration of preparative
regimen or as an administration of stem cells graft without
conditioning from the same donor. In general, regrafting af-
ter a preparative conditioning can successfully improve PGF
with response rates of 66% to 100%. However, because of the
high GVHD rate (40% to 60%), infectious complications, and
consequently increased nonrelapse mortality (NRM) (50% to
60%), the overall survival (OS) after such approach is poor
(20% to 35%) [3-5]. The leading causes of death after second
transplantation were severe infections (44%) [3]. The ﬁrst
attempt to improve survival by reducing the NRM was made
by Remberger et al. [6], who administered an unmanipulated
SCB without conditioning in 16 patients with PGF. The
improvement of hematopoiesis was achieved in majority of
the patients resulting in a 3-years OS rate of 43%. However,Transplantation.
Table 1
Patients’ Characteristics
Characteristics No. of Patients
N 32
Age, median (range), yr 54 (20-69)
Sex:
Male 22 (69%)
Female 10 (31%)
Disease:
Primary myeloﬁbrosis 14 (44%)
Chronic myeloid leukemia 4 (13%)
Severe aplastic anemia 4 (13%)
Non-Hodgkin’s lymphoma 3 (9%)
Acute myeloblastic leukemia 2 (6%)
Acute lymphoblastic leukemia 2 (6%)
Multiple myeloma 2 (6%)
Myelodysplastic syndrome 1 (3%)
Karnofsky status at allo-HSCT:
100% 10 (31%)
90% 17 (53%)
70% 5 (16%)
Donor type:
MRD 11 (34%)
MUD 15 (47%)
MMUD 6 (19%)
CMV status (P/D):
Pos/pos 19 (59%)
Pos/neg 4 (13%)
Neg/neg 5 (16%)
Neg/pos 4 (13%)
ABO status (P/D):
Major incompatibility 13 of 31 (42%)
Minor incompatibility 11 of 31 (35%)
Combined incompatibility 1 of 31 (3%)
Identical 6 of 31 (20%)
Sex constellation (P/D):
Identical 19 (59%)
Female/male 7 (22%)
Male/female 6 (19%)
Conditioning regimen:
MAC 9 (28%)
RIC 23 (72%)
TBI in conditioning regimen:
Yes 8 (25%)
No 24 (75%)
In vivo T cell depletion:
Yes 27 (84%)
No 5 (16%)
Acute GVHD:
Grade II 6 (19%)
Grade III 4 (13%)
Chronic GVHD:
Limited 1 (3%)
Extensive 1 (3%)
CMV reactivation
Yes 16 (50%)
No 16 (50%)
Poor graft function:
Primary 13 (41%)
Secondary 19 (59%)
Interval between allo-HSCT and boost:
6 months 20 (63%)
>6 months 12 (37%)
Data presented are n (%) unless otherwise indicated.
allo-HSCT indicates allogeneic hematopoietic stem cell transplantation;
MRD, matched related donor; MUD, matched unrelated donor; MMUD,
mismatched unrelated donor; P, patient; D, donor; MAC, myeloablative
conditioning; RIC, reduced-intensity conditioning; TBI, total body irradia-
tion; GVHD, graft-versus-host disease; CMV, cytomegalovirus.
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Min et al. [7] administered an unmanipulated SCB to 11 pa-
tients without prior conditioning and observed a favorable 3-
year OS of 71% with a GVHD rate of 30%. Taking into account
the fact that the persistence of T cells in graft might be
associated with an increased GVHD rate, the use of a CD34
positiveeselected SCB was suggested [8-11]. In our previous
studies on 11 patients, we reported a possibility of improving
PGF without development of GVHD by using a CD34 pos-
itiveeselected SCB [9-11]. Here, we performed a retrospec-
tive analysis of a group of 32 PGF patients (including the 11
previous patients) after allogeneic HSCT to evaluate the
safety, efﬁcacy, and survival outcomes after the administra-
tion of the CD34þ SCB.
PATIENTS AND METHODS
Patients
Patients’ characteristics are summarized in Table 1. A total of 32 patients
with PGF received a CD34þ SCB of peripheral blood stem cells from 2002 to
2011 at the Department for Stem Cell Transplantation of the University
Medical Center Hamburg-Eppendorf, Hamburg, Germany and the Depart-
ment for Stem Cell Transplantation of the Institut Paoli Calmettes, Marseille,
France, without additional conditioning. Almost one half of the patients in
this cohort had a diagnosis of primary myeloﬁbrosis (n ¼ 14, 44%) and un-
derwent transplantation with major ABO incompatibility. All patients gave
written informed consent. The study was conducted in accordance with the
principles of the Declaration of Helsinki. A total of 12 of 32 (38%) patients
required regular transfusions of blood products (erythrocyte and platelet
concentrates) at least everymonth before allogeneic HSCT. At the time of the
SCB administration, no patient received immunosuppressive medications
and had full donor chimerism. The median neutrophil count at the time of
the boost administration was 1.1 x 109/L (range, .2 to 1.2), the median
platelet count was 20 x 109/L (range, 8 to 120), and the median hemoglobin
concentration was 8.3 g/dL (range, 7.6 to 11.0).
Deﬁnitions
Engraftment of neutrophils was deﬁned as the ﬁrst of 3 consecutive days
when the absolute neutrophil count was .5 x 109/L without granulocyte
colony-stimulating factor (5 mkg/kg body weight [b.w.]) stimulation.
Engraftment of platelets was deﬁned as the ﬁrst of 3 consecutive days when
the platelet count was 20 x 109/L, independent from platelet substitution.
PGF was deﬁned by cytopenia in at least 2 hematopoietic lines
(neutrophil count 1.5 x 109/L, platelet count 30 x 109/L, Hb 8.5 g/dL) for
at least 2 consecutive weeks beyond day þ14 post transplantation (primary
PGF) or at any time point after achieving of engraftment (secondary PGF),
with transfusion requirement, in the presence of full donor chimerism and
in the absence of severe GVHD, cytomegalovirus (CMV) reactivation, relapse,
or drug-related myelosuppression. These cut-offs were suggested as being
clinically critical regarding the development of infectious complications,
bleeding, or anemic syndrome.
Hematological improvement (HI) was deﬁned as neutrophils >1.5 x
109/L, platelets >30 x 109/L, and hemoglobin >8.5 g/dL. These cut-offs were
chosen as the minimal sufﬁcient values that do not require blood or platelet
substitution and are associated with reduced risk of infectious complica-
tions. Hematological response (HR) was deﬁned as neutrophils >2.5 x 109/L,
platelets >100 x 109/L, and hemoglobin >10 g/dL. Patients were also scored
for transfusion independence and analyzed for hematological response on
daysþ14,þ20,þ30,þ60, and thereafter after the infusion of CD34þ selected
allografts.
aGVHD after SCB was deﬁned according to criteria suggested by
Glucksberg et al. [17], and cGVHD was deﬁned as limited and extensive [18].
Initial Allogeneic HSCT and Risk Factors
The main transplantation characteristics are represented in Table 1. The
majority of patients received allografts from unrelated donors (matched, n¼
15; mismatched, n ¼ 6). In detail, 4 of 6 patients had mismatches in 1 of 10
(A, n¼ 1; DQB1, n¼ 3), whereas the remaining 2 patients hadmismatches in
2 of 10 HLA loci (Cw/DQB1, and DRB1/DQB1).
Diagnosis of CMV Reactivation
Samples for detection of CMV were taken weekly during the ﬁrst 6
months after allogeneic HSCT. CMV load was measured weekly by quanti-
tative real-time PCR on genomic DNA from the cellular fraction of whole
blood. The delta-CT method was used to quantify viral genome load in
comparison to human HCK gene expression. A CT value of 12 was thethreshold at or below which the CMV PCR was regarded positive. Values
above 12 were regarded as borderline.
CD34þ Selected SCB
Positive CD34þ selections were applied according to the manufacturer’s
instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were
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Figure 1. Cumulative incidence of neutrophil, platelet and hemoglobin
recovery after SCB.
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magnetic microbeads (Miltenyi Biotec) and washed with subsequent puri-
ﬁcation of CD34þ positive cells using CliniMACS technology. After selection,
cells present in the positive and negative fractionswere counted and stained
with CD34þ phycoerythrin (Becton Dickinson) mAbs, recognizing another
epitope other than the epitope recognized by the antibodies coupled to the
microbeads. For exclusion of dead cells, 7-amino actinomycin D (PharMin-
gen, San Diego, CA) was included in all fractions. After staining, cells were
measured on a ﬂow cytometer. Recovery of normal stem cells was deﬁned as
the absolute number of CD34þ positive viable cells present in the positive
fraction as a percentage of the absolute number of CD34þ positive viable
cells present in the peripheral blood stem cells transplants before selection.
The median interval from HSCT to CD34þ SCB was 5 months (range, 2 to
228). The majority of patients with primary PGF (11 of 13, 85%) received a
CD34þ SCB during the ﬁrst 6 months, whereas the majority of patients with
a secondary PGF (10 of 19, 53%) received the boost after 6 months from the
development of PGF. The median amount of CD34þ cells was 3.4 x 106/kg
b.w. (range, .96 to 8.30). The median amount of CD3þ T cells was 9 x 103/kg
b.w. (range, 2 to 70).
Statistical Evaluation
Categorical variables were compared by using of chi-square test.
Continuous and ordinary variables were compared using the Mann-
Whitney U test. Probabilities of OS and progression-free survival, and uni-
variate analysis of these time-dependent noncompeting variables were
calculated with Kaplan-Meier method and log-rank test. Probabilities of
NRM, relapse, aGVHD, and cGVHD were estimated by using the cumulative
incidences method. Variables with a potential impact on survival were
entered to proportional hazards Cox regression analysis. The analysis of the
time-dependent competing variables (NRM/relapse incidence; acute/
chronic GVHD) was performed with a subdistributive hazards ratio model.
SPSS version 17.0 (Munich, Germany) was used and the cumulative inci-
dence analysis was performed with the R statistics software package [19].
RESULTS
Primary and Secondary PGF
There were 13 (41%) primary and 19 (59%) secondary PGF
patients. A total of 18 patients (56%) experienced the PGF in
2 hematopoietic lines and 14 patients (44%) in 3 hemato-
poietic lines. The number of patients with trilineage cyto-
penia was similar in patients with primary and secondary
PGF (7 of 13 [54%] versus 7 of 19 [37%], respectively, P ¼ .47).
We were not able to ﬁnd any signiﬁcant associations be-
tween the type of PGF and the following factors: patient’s
and donor age, disease type, donor/patient sex constellation,
donor/patient CMV serostatus constellation, donor/patient
ABO blood group constellation, donor type (related/unre-
lated; HLA match/HLA mismatch), intensity of conditioning,
in vivo T cell depletion, and total body irradiation (TBI) in
conditioning.
HI and HR
HI was evaluable in all 32 patients (Figure 1). Twenty-six
patients (81%) achieved HI after a median of 30 days (range,
14 to 120). There was no signiﬁcant difference in the re-
sponses between patients with primary and secondary PGF.
A total of 7 of 32 patients (22%) fulﬁlled criteria for complete
hematological remission (CHR) at day þ30 after the SCB. All
responding patients maintained their responses during the
follow-up period.
Six patients (9%) showed no response. One patient un-
derwent a second allogeneic HSCT and another 5 patients
died because of severe infectious complications.
Factors Inﬂuencing the Hematological Improvement and
Response
The disease type, patient’s and donor age, the character of
cytopenia (bi- or trilineage), sex constellation, CMV seros-
tatus, ABO-status, TBI in conditioning, interval from the
initial allograft to boost, and the median numbers of CD34þand CD3þ cells had no impact on the rate and on the time to
achievement of HI or HR.
The overall response rate in patients who received CD34þ
SCB from related donor was higher than in recipients of
unrelated boosts (11 of 11 [100%] versus 15 of 21 [71%], P ¼
.07). The median time to response for recipients of related
boosts was shorter than that for recipients of unrelated
boosts (dayþ20 versus dayþ30, P¼ .04). Of the patients who
received grafts from younger donors (35 years, n ¼ 10), all
developed HI. Of the patients who received grafts from older
donors (>35 years, n ¼ 22), 6 did not show HI. These 6 pa-
tients received grafts from unrelated donor (P ¼ .26).
Patients who experienced HR (n ¼ 7) were signiﬁcantly
younger (median age of 39 versus 54 years [P ¼ .041] and
received CD34þ SCB from younger donors (median age of 35
versus 43 years [P ¼ .036]). Of the patients who received
grafts from related donors (n ¼ 11) 3 of 5 (60%) recipients of
allografts from the younger donors (35 years) developed
HR. No patients who received SCB from older related donors
(>35 years, n¼ 6) did showHR (P¼ .06). Of the patients who
received boosts from unrelated donors (n ¼ 21), 2 recipients
with younger donor (40%) and 3 of those with older donor
(19%) developed HR (P ¼ .55).
Further, we observed no correlation between the donor’s
age and amount of CD34þ cells in the boost (r ¼ .075). Also,
we did not observe signiﬁcant difference between the me-
dian amount of CD34þ cells in younger (35 years, 3.5 x 106/
kg b.w.) and older (>35 years, 6.0 x 106/kg b.w.; P ¼ .16).GVHD
A total of 6 patients developed aGVHD (grade II, n ¼ 2;
grade III, n ¼ 2; grade IV, n ¼ 2) after the CD34þ SCB
administration. The cumulative incidence of aGVHD at 100
days after the boost administration was 17% (95% conﬁdence
interval [CI], 3% to 31%) (Figure 2). The median time to the
GVHD manifestation was day þ20 (range, 7 to 84). A total of
22 patients were alive after dayþ100 after the boost. Chronic
GVHD developed in 6 patients (limited, n ¼ 4; extensive, n ¼
2) at a median of 201 days (range, 104 to 411) after the boost
administration. One patient developed extensive cGVHD
after the second allogeneic HSCT; 2 patients with aGVHD and
3 patients with cGVHD after the boost had already experi-
enced an aGVHD after the initial transplantation. The cu-
mulative incidence of cGVHD at 1 year after the boost was
26% (95% CI, 16% to 46%) (Figure 2). We observed no signiﬁ-
cant correlations between the donor status (related versus
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Figure 2. Cumulative incidence of acute and chronic GVHD after SCB.
Figure 3. Probability of survival after SCB.
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GVHD.
Factors Associated with GVHD
The disease type, patient’s and donor age, donor type
(match versus mismatch; related versus unrelated), sex
constellation, CMV serostatus, ABO-status, TBI in condition-
ing, median number of CD34þ cells, and the median interval
between the boost and the initial allogeneic HSCT had no
signiﬁcant effect on the development of GVHD. The CD3þ cell
dose in the graft was signiﬁcantly associated with the
development of aGVHD: patients who developed aGVHD
received amedian of 32 x 103 CD3þ/kg b.w., whereas patients
without aGVHD received a median of 8 x 103 CD3þ/kg b.w.
(P ¼ .02). We did not ﬁnd any signiﬁcant inﬂuence of the
CD3þ cell dose on the cumulative incidence of cGVHD.
Survival
At a median follow-up of 30 months (range, 4 to 107) 16
patients (6 nonresponding patients, 6 patients with HI, and 4
patients with CHR) had died. Of those patients, the majority
(11 of 16, 69%) received SCB frommatched unrelated donors,
and experienced positive CMV status (11 of 16, 69%) and
either major (6 of 16, 38%) or minor (6 of 16, 38%) ABO-
incompatibility. The causes of death included sepsis and/or
severe infection (n ¼ 8), severe aGVHD (n ¼ 3), extensive
cGVHD with concomitant infection (n ¼ 1), relapse/disease
progression (n ¼ 3), and cerebral hemorrhage (n ¼ 1). Of 6
patients who developed aGVHD, 3 expired: all those patients
received SCB from matched unrelated donors with a median
of 27 x 103 CD3þ/kg b.w. and already had aGVHD (grade I to
III) after the allogeneic HSCT. The fourth patient developed a
severe viral infection, which was associated with treatment
of extensive cGVHD. One patient who experienced HI
remained thrombocytopenic (<20 x 109/L) and died because
of a cerebral hemorrhage.
Of the 16 living patients, 12 patients achieved HI, 3
experienced HR, and 1 achieved HR after a second allogeneic
HSCT. The 2-year probability of OS was 45% (95% CI, 27% to
63%) (Figure 3). We did not observe any signiﬁcant factors
associated with development of response (donor type and
donor age) on the survival outcome for all patients.
DISCUSSION
PGF is a rare complication of allogeneic HSCT that is
associated with increased mortality because of developmentof severe infectious and hemorrhagic complications.We here
report on a retrospective evaluation of 32 PGF patients who
received a CD34þ SCB without additional conditioning with a
follow-up period of almost 10 years. All patients receiving
SCB were considered. The most important risk factors for
developing a PGF in our series were diagnosis of primary
myeloﬁbrosis (44% of cases) and major ABO-incompatibility
(42% of cases). Other factors included prior alloimmuniza-
tion, unrelated grafts, reduced intensity of conditioning, or
T cell depletion. The aim of the study was to evaluate the
efﬁcacy of the CD34þ-selected boost with regards to
response kinetics, response rate, and stability as well as the
safety and survival outcomes after the CD34þ SCB adminis-
tration. The limitations of this analysis were the heteroge-
neity of the patients and retrospective nature of the study.
First, we observed an overall HI rate of 81% (HR: n ¼ 7,
22%). All patients maintained the response up to the last
follow up. The patients who achieved HI required no regular
transfusions of blood or platelets. The median time to
response was 25 days (range, 14 to 120). Although the range
of the interval to response was widespread, the majority of
the patients developed HI during the ﬁrstmonths after boost.
We showed that the recipients of related boosts responded
faster as those patients who received boosts from unrelated
donors. Additionally, we noticed a trend to an increased
overall rate of HI for related donors. Patients who experi-
enced HR were younger and received boosts from younger
donors. Although we did not see any signiﬁcant correlation
between the stem cell richness of boost and donor age, it
should be taken into account that the population of patients
was probably too small and, therefore, the statistical power
was limited. Another possible aspect in this setting could be
associated with the quality of stem cells from younger do-
nors. Nevertheless, we were not able to ﬁnd a prognostic
impact of these factors (donor type and donor age) either on
the development of response or on survival.
As the majority of published data regarding the use of
CD34þ selected SCB are case reports, it appears to be difﬁcult
to compare our results with those from other authors. For
instance, Larocca et al., who studied patients with different
hematologic diseases after CD34þ-selected SCB infusion (n ¼
20), reported that majority of those (80%) did not fulﬁll the
criteria for CHR on the dayþ30 and remained cytopenic. This
corresponds to a response rate of 25% at day þ30 in our
E. Klyuchnikov et al. / Biol Blood Marrow Transplant 20 (2014) 382e386386study. Conversely to our study, the authors were not able to
reveal any effect of the donor type, patient’s age, and donor
age on the response [8].
Second, the incidence of acute (day þ100) and chronic
GVHD (1 year) was 17% and 26%, respectively. The recipients
of SCB from unrelated donors with a high amount of T cells
and a positive GVHD history could represent a risk group for
the development of GVHD after SCB. However, the overall
GVHD rate in the present study was lower as compared with
results after a second allogeneic HSCT (40% to 60%) [3-5] or
administration of an unmanipulated SCB (30% to 50%) [6,7].
The 2-year OS of 45% in our study was acceptable but not
optimal. Although GVHD remains an important cause of
death (4 of 16, 25%), the main causes of deaths were severe
infectious complications due to prolonged cytopenia after
the initial allogeneic HSCT (8 of 16, 50%). Notably, 4 of 8
patients who developed CHR died because of sepsis/severe
infections.
Thus, taking into account the retrospective nature and
heterogeneity of patients in the study, we conﬁrmed that the
use of CD34þ-selected stem cell boost without chemo-
therapy or immunosuppressive conditioning could be asso-
ciated with improved survival outcomes. Although we did
not see any signiﬁcant inﬂuence of diagnosis on the out-
comes, the fact that almost one half of our patients had a
diagnosis of a primary myeloﬁbrosis remains important and
requires further investigation. The younger patients who
receive the SCB from younger related donor might represent
the best population that has beneﬁt from this approach. For
patients with GVHD history, who receive SCB with increased
amount of T cells, possible immunosuppression should be
discussed. Finally, the earlier proceeding of PGF patients to
SCB might improve the outcomes by reducing the time of
neutropenia.
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